FDA Chides Mylan Over Puerto Rico Plant Violations
The FDA sent the generic-drug company a warning letter Oct. 13 regarding what it called significant violations of current good manufacturing practice regulations for finished pharmaceuticals at its Caguas, Puerto Rico, plant. The agency said it inspected the facility from Jan. 24 to Feb. 24.
“We intend to work closely with FDA...
To view the full article, register now.